Combination Zibotentan/Dapagliflozin Reduces Albuminuria in CKD
Results of the ZENITH-CKD trial provide evidence of the safety and efficacy profile of combination zibotentan plus dapagliflozin in patients with chronic kidney disease.
United States Sharon Barr Hiddo Heerspink Biopharmaceuticals Research George Clinical Institute Hiddo Jl Heerspink American Society Of Nephrology Kidney Week
Source: hcplive.com